Somaili Mohammed, Oraibi Omar, Mohrag Mostafa, Hommadi Abdelrahman, Moafa Esam, Kulaybi Abdulrahman, Shobayli Sahar, Moafa Razan, Mhgfory Ghadah, Jaafari Afaf, Shami Ayman, Majrashi Khalid
Internal Medicine, Jazan University, Jazan, SAU.
Endocrinology, Jazan University, Jazan, SAU.
Cureus. 2022 Apr 19;14(4):e24284. doi: 10.7759/cureus.24284. eCollection 2022 Apr.
Sodium-glucose cotransporter inhibitors are promising medications for improving cardiovascular outcomes in diabetic and non-diabetic patients. The baseline characteristics associated with its prescription in Jazan, Saudi Arabia, are still lacking.
This study aims to determine the baseline characteristics associated with its prescription among type 2 diabetic patients in the Jazan region.
A retrospective cohort study of adult patients with type 2 diabetes mellitus (T2DM) in Jazan region, Saudi Arabia, who received a prescription of sodium-glucose cotransporter 2 inhibitors (SGLT2i) from June 2016 to December 2021 was conducted. Categorical baseline characteristics are reported as frequencies, and proportion and continuous variables are reported as means (SD). The crude odds and adjusted ratio (OR) (95% CI) for SGLT2i prescription were then calculated using univariate and multivariate logistic regression analysis.
A total of 370 patients who satisfied the inclusion criteria were included in this study. There were 133 patients (36%) who had been prescribed SGLT2i over a median follow-up of five years. Characteristics associated with the prescription were female gender (adjusted odds ratio [aOR]: 2.2, 95% Cl: 1.3-3.9), endocrinologist doctors (aOR: 2.4, 95% Cl: 1.3-4.5), patients who had visited the center four times or more (aOR: 10.9, 95% Cl: 4.6-25.9), patients who have evidence of DM retinopathy (aOR: 9.7, 95% Cl: 2.9-31.7), or patients who are morbidly obese (aOR: 4.1, 95% Cl: 1.1-14.8).
The sodium-glucose cotransporter inhibitors are under-prescribed among type 2 diabetic patients in the Jazan region despite their availability. Further studies are warranted to address the potential barriers to prescriptions among different medical specialties.
钠-葡萄糖协同转运蛋白抑制剂是改善糖尿病和非糖尿病患者心血管结局的有前景的药物。沙特阿拉伯吉赞地区与其处方相关的基线特征仍然缺乏。
本研究旨在确定吉赞地区2型糖尿病患者中与其处方相关的基线特征。
对沙特阿拉伯吉赞地区2016年6月至2021年12月期间接受钠-葡萄糖协同转运蛋白2抑制剂（SGLT2i）处方的成年2型糖尿病（T2DM）患者进行了一项回顾性队列研究。分类基线特征以频率和比例报告，连续变量以均值（标准差）报告。然后使用单变量和多变量逻辑回归分析计算SGLT2i处方的粗比值和调整比值（OR）（95%可信区间）。
本研究共纳入370例符合纳入标准的患者。在中位随访五年期间，有133例患者（36%）被开具了SGLT2i。与处方相关的特征为女性（调整后比值比[aOR]：2.2，95%可信区间：1.3 - 3.9）、内分泌科医生（aOR：2.4，95%可信区间：1.3 - 4.5）、就诊中心4次或更多次的患者（aOR：10.9，95%可信区间：4.6 - 25.9）、有糖尿病视网膜病变证据的患者（aOR：9.7，95%可信区间：2.9 - 31.7）或病态肥胖患者（aOR：4.1，95%可信区间：1.1 - 14.8）。
尽管钠-葡萄糖协同转运蛋白抑制剂在吉赞地区2型糖尿病患者中已可获得，但处方量不足。有必要进行进一步研究以解决不同医学专科中处方的潜在障碍。
